Yahoo Finance

Estimated Discount To Fair Value: 21.2%

CellaVision AB (publ) is trading at SEK 197.6, below its estimated fair value of SEK 250.81, suggesting potential undervaluation based on cash flows. The company's earnings are forecast to grow at 19.4% annually, exceeding the Swedish market's growth rate of 16.6%. Despite a decline in Q4 sales and net income compared to the previous year, CellaVision maintains a positive outlook with high forecasted return on equity and proposed dividends aligning with its policy.

• Our comprehensive growth report raises the possibility that CellaVision is poised for substantial financial growth.

• Get an in-depth perspective on CellaVision's balance sheet by reading our health report here.

Vimian Group

Overview: Vimian Group AB (publ) operates in the global animal health industry and has a market capitalization of SEK19.64 billion.

Operations: Vimian Group AB's revenue is derived from four main segments: Medtech (€123.90 million), Diagnostics (€20.90 million), Specialty Pharma (€172 million), and Veterinary Services (€58.20 million).

Estimated Discount To Fair Value: 33.6%

Vimian Group AB is trading at SEK 37.48, significantly below its estimated fair value of SEK 56.43, highlighting potential undervaluation based on cash flows. The company reported Q1 sales of €107.5 million and net income of €4.3 million, showing improvement from the previous year. Earnings are forecast to grow substantially at 42.3% annually over the next three years, outpacing the Swedish market's growth rate and indicating strong future prospects despite a low return on equity forecast.

• Our growth report here indicates Vimian Group may be poised for an improving outlook.

• Click here and access our complete balance sheet health report to understand the dynamics of Vimian Group.

Turning Ideas Into Actions

• Access the full spectrum of 180 Undervalued European Stocks Based On Cash Flows by clicking on this link.

• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.

• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HLSE:REG1V OM:CEVI and OM:VIMIAN.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com